Compare PEB & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | NBTX |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 2009 | 2018 |
| Metric | PEB | NBTX |
|---|---|---|
| Price | $18.35 | $41.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | $13.30 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 2.0M | 139.0K |
| Earning Date | 04-28-2026 | 03-31-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,475,544,000.00 | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.53 | N/A |
| 52 Week Low | $9.99 | $8.03 |
| 52 Week High | $19.93 | $57.14 |
| Indicator | PEB | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 52.17 |
| Support Level | $18.35 | $34.97 |
| Resistance Level | $19.73 | $41.06 |
| Average True Range (ATR) | 0.51 | 2.19 |
| MACD | -0.01 | 0.19 |
| Stochastic Oscillator | 57.28 | 53.63 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.